KLRK1 and breast cancer: The decreased NKG2D mRNA expression observed in BC patients aligns with previous findings by Park et al., where patients with ovarian, breast and cervical cancer exhibited reduced NKG2D expression, leading to impaired NK cell cytotoxicity [16] and tumor progression [18].